Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jiedu Yizhi Formula vs Donepezil in Alzheimer's Disease
NCT06393413Phase 1Completed
- Sponsor
- Changchun University of Chinese Medicine
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- HM (Herbal Medicine), Combination therapy, NPI (Non-Pharmacological Intervention)
- Countries
- 1
01
Overview
Phase 1, randomised trial of Jiedu Yizhi Formula in Alzheimer's disease (AD) (2 arms), sponsored by Changchun University of Chinese Medicine. Primary endpoints: Mini-Mental State Examination at 24 weeks, Montreal Cognitive Assessment at 24 weeks and 2 more. Started Dec 2022; status: completed.
02
Drugs
Jiedu Yizhi Formula
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06393413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393413.